These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 22403241

  • 1. Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.
    Liu Q, Chen Y, Auger-Messier M, Molkentin JD.
    Circ Res; 2012 Apr 13; 110(8):1077-86. PubMed ID: 22403241
    [Abstract] [Full Text] [Related]

  • 2. TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways.
    Li L, Chen Y, Li J, Yin H, Guo X, Doan J, Molkentin JD, Liu Q.
    Sci Rep; 2015 Nov 13; 5():16626. PubMed ID: 26564789
    [Abstract] [Full Text] [Related]

  • 3. Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.
    Luo Y, Jiang N, May HI, Luo X, Ferdous A, Schiattarella GG, Chen G, Li Q, Li C, Rothermel BA, Jiang D, Lavandero S, Gillette TG, Hill JA.
    Circulation; 2021 Jul 06; 144(1):34-51. PubMed ID: 33821668
    [Abstract] [Full Text] [Related]

  • 4. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD.
    Circ Res; 2004 Jan 09; 94(1):110-8. PubMed ID: 14656927
    [Abstract] [Full Text] [Related]

  • 5. GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity.
    Hullmann JE, Grisanti LA, Makarewich CA, Gao E, Gold JI, Chuprun JK, Tilley DG, Houser SR, Koch WJ.
    Circ Res; 2014 Dec 05; 115(12):976-85. PubMed ID: 25332207
    [Abstract] [Full Text] [Related]

  • 6. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D, Kim JM, Cha H, Oh JG, Park J, Yun SH, Ju ES, Jeon ES, Hajjar RJ, Park WJ.
    Circ Res; 2008 Mar 28; 102(6):711-9. PubMed ID: 18258855
    [Abstract] [Full Text] [Related]

  • 7. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
    Liu W, Deng J, Ding W, Wang G, Shen Y, Zheng J, Zhang X, Luo Y, Lv C, Wang Y, Chen L, Yan D, Boudreau RL, Song LS, Liu J.
    Circ Heart Fail; 2017 Jun 28; 10(6):. PubMed ID: 28611128
    [Abstract] [Full Text] [Related]

  • 8. The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice.
    Chiang CS, Huang CH, Chieng H, Chang YT, Chang D, Chen JJ, Chen YC, Chen YH, Shin HS, Campbell KP, Chen CC.
    Circ Res; 2009 Feb 27; 104(4):522-30. PubMed ID: 19122177
    [Abstract] [Full Text] [Related]

  • 9. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
    Donaldson C, Eder S, Baker C, Aronovitz MJ, Weiss AD, Hall-Porter M, Wang F, Ackerman A, Karas RH, Molkentin JD, Patten RD.
    Circ Res; 2009 Jan 30; 104(2):265-75, 11p following 275. PubMed ID: 19074476
    [Abstract] [Full Text] [Related]

  • 10. NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity.
    Zhang X, Lei F, Wang XM, Deng KQ, Ji YX, Zhang Y, Li H, Zhang XD, Lu Z, Zhang P.
    J Am Heart Assoc; 2020 Aug 18; 9(16):e016419. PubMed ID: 32805187
    [Abstract] [Full Text] [Related]

  • 11. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
    Mohamed BA, Barakat AZ, Zimmermann WH, Bittner RE, Mühlfeld C, Hünlich M, Engel W, Maier LS, Adham IM.
    J Mol Cell Cardiol; 2012 Oct 18; 53(4):459-68. PubMed ID: 22884543
    [Abstract] [Full Text] [Related]

  • 12. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
    Grebe C, Klingebiel TM, Grau SP, Toischer K, Didié M, Jacobshagen C, Dullin C, Hasenfuss G, Seidler T.
    Cardiovasc Res; 2011 Jun 01; 90(3):521-8. PubMed ID: 21273244
    [Abstract] [Full Text] [Related]

  • 13. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy.
    Facundo HT, Brainard RE, Watson LJ, Ngoh GA, Hamid T, Prabhu SD, Jones SP.
    Am J Physiol Heart Circ Physiol; 2012 May 15; 302(10):H2122-30. PubMed ID: 22408028
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.
    Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, Molkentin JD, Drexler H, Wollert KC.
    Proc Natl Acad Sci U S A; 2002 Aug 20; 99(17):11363-8. PubMed ID: 12177418
    [Abstract] [Full Text] [Related]

  • 15. Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway.
    Finsen AV, Lunde IG, Sjaastad I, Østli EK, Lyngra M, Jarstadmarken HO, Hasic A, Nygård S, Wilcox-Adelman SA, Goetinck PF, Lyberg T, Skrbic B, Florholmen G, Tønnessen T, Louch WE, Djurovic S, Carlson CR, Christensen G.
    PLoS One; 2011 Aug 20; 6(12):e28302. PubMed ID: 22164265
    [Abstract] [Full Text] [Related]

  • 16. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A.
    Maejima Y, Usui S, Zhai P, Takamura M, Kaneko S, Zablocki D, Yokota M, Isobe M, Sadoshima J.
    Circ Heart Fail; 2014 May 20; 7(3):479-90. PubMed ID: 24526353
    [Abstract] [Full Text] [Related]

  • 17. GSK-3β/NFAT Signaling Is Involved in Testosterone-Induced Cardiac Myocyte Hypertrophy.
    Duran J, Oyarce C, Pavez M, Valladares D, Basualto-Alarcon C, Lagos D, Barrientos G, Troncoso MF, Ibarra C, Estrada M.
    PLoS One; 2016 May 20; 11(12):e0168255. PubMed ID: 27977752
    [Abstract] [Full Text] [Related]

  • 18. Cdc42 is an antihypertrophic molecular switch in the mouse heart.
    Maillet M, Lynch JM, Sanna B, York AJ, Zheng Y, Molkentin JD.
    J Clin Invest; 2009 Oct 20; 119(10):3079-88. PubMed ID: 19741299
    [Abstract] [Full Text] [Related]

  • 19. Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4.
    Zou J, Le K, Xu S, Chen J, Liu Z, Chao X, Geng B, Luo J, Zeng S, Ye J, Liu P.
    Mol Cell Endocrinol; 2013 May 06; 370(1-2):103-12. PubMed ID: 23518069
    [Abstract] [Full Text] [Related]

  • 20. Cardiac remodeling is not modulated by overexpression of muscle LIM protein (MLP).
    Kuhn C, Frank D, Dierck F, Oehl U, Krebs J, Will R, Lehmann LH, Backs J, Katus HA, Frey N.
    Basic Res Cardiol; 2012 May 06; 107(3):262. PubMed ID: 22421737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.